Abstract
The use and indications of anti-vascular endothelial growth factors (VEGF) are rapidly expanding, evolving and undergoing refinement in retinal diseases. This manuscript attempts to perform a critical appraisal of the diaspora of limited information available on the non- traditional applications (outside of AMD, DR and vascular occlusive diseases) and synthesize a review. As with any newer drug, only longitudinal studies will determine the true inherent value no matter how broad the current popular appeal appears to be due to very positive press. Although these drugs appear to be very effective in conventional applications, it is wise to deliberate prior to non-conventional use.
Keywords: Bevacizumab, choroidal neovascularization, myopia, retinopathy of prematurity, Vascular endothelial growth factor, VEGF, Coloboma, Angioid streaks, Choroidal rupture, chorioretinopathy
8